AU6087399A - Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid - Google Patents

Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid Download PDF

Info

Publication number
AU6087399A
AU6087399A AU60873/99A AU6087399A AU6087399A AU 6087399 A AU6087399 A AU 6087399A AU 60873/99 A AU60873/99 A AU 60873/99A AU 6087399 A AU6087399 A AU 6087399A AU 6087399 A AU6087399 A AU 6087399A
Authority
AU
Australia
Prior art keywords
oral dosage
dosage form
discrete oral
discrete
alginic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU60873/99A
Other languages
English (en)
Inventor
Samuel Bruce Balik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU6087399A publication Critical patent/AU6087399A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU60873/99A 1998-09-28 1999-09-24 Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid Abandoned AU6087399A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10211298P 1998-09-28 1998-09-28
US60102112 1998-09-28
PCT/EP1999/007117 WO2000018406A1 (en) 1998-09-28 1999-09-24 Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid

Publications (1)

Publication Number Publication Date
AU6087399A true AU6087399A (en) 2000-04-17

Family

ID=22288187

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60873/99A Abandoned AU6087399A (en) 1998-09-28 1999-09-24 Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid

Country Status (17)

Country Link
EP (1) EP1117407A1 (no)
JP (1) JP2002525328A (no)
KR (1) KR20010075385A (no)
CN (1) CN1328459A (no)
AR (1) AR022673A1 (no)
AU (1) AU6087399A (no)
BR (1) BR9914096A (no)
CA (1) CA2345638A1 (no)
CZ (1) CZ20011142A3 (no)
HU (1) HUP0103459A2 (no)
IL (1) IL142054A0 (no)
MA (1) MA26693A1 (no)
NO (1) NO20011555L (no)
PE (1) PE20001087A1 (no)
PL (1) PL346877A1 (no)
TR (1) TR200100863T2 (no)
WO (1) WO2000018406A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1220673A2 (en) * 1999-10-13 2002-07-10 Glaxo Group Limited Morpholinol derivatives for the treatment of obesity
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use

Also Published As

Publication number Publication date
IL142054A0 (en) 2002-03-10
CA2345638A1 (en) 2000-04-06
PL346877A1 (en) 2002-03-11
JP2002525328A (ja) 2002-08-13
WO2000018406A1 (en) 2000-04-06
NO20011555D0 (no) 2001-03-27
NO20011555L (no) 2001-03-27
EP1117407A1 (en) 2001-07-25
TR200100863T2 (tr) 2001-07-23
CN1328459A (zh) 2001-12-26
MA26693A1 (fr) 2004-12-20
BR9914096A (pt) 2001-07-31
KR20010075385A (ko) 2001-08-09
HUP0103459A2 (hu) 2002-01-28
AR022673A1 (es) 2002-09-04
PE20001087A1 (es) 2000-10-20
CZ20011142A3 (cs) 2001-09-12

Similar Documents

Publication Publication Date Title
KR20100121509A (ko) 구강 내 붕괴정
CN101925349A (zh) 替马西泮的口腔崩解片组合物
RU2007123565A (ru) Композиции разагилина, распадающиеся в ротовой полости
CA2687124A1 (en) Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
JP2009513530A5 (no)
EP1353650A2 (en) Process for preparing non-hygroscopic sodium valproate composition
JP2005132801A (ja) 口腔内崩壊錠
WO2007058397A1 (en) A dispersible tablet comprising the mixture of amoxicillin and clavulanic acid or its salts and processes for preparing the same
EP4062906A1 (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
JP5318400B2 (ja) レボフロキサシン含有錠剤
JP3774814B2 (ja) システイン類の不快な臭気又は味が軽減された組成物
JP5295506B2 (ja) レボフロキサシン含有錠剤
TWI689306B (zh) 經安定化而成之醫藥組成物
EP3501506B1 (en) Pharmaceutical tablet composition comprising brexpiprazole
AU6087399A (en) Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid
JP4766941B2 (ja) システイン類の不快な臭気又は味が軽減された組成物
MXPA01003130A (en) Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid
JPWO2003075919A1 (ja) 塩酸ピルジカイニド含有錠剤（乾式）
JPWO2008081774A1 (ja) リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤
JP2002020282A (ja) プラバスタチン含有組成物
JP7195660B1 (ja) 口腔内崩壊錠
JPWO2018079570A1 (ja) 安定な医薬組成物
JP6982290B2 (ja) オンジエキス含有内服用固形医薬製剤
JP4393119B2 (ja) ヨウ化イソプロパミド含有製剤
EP2979698A1 (en) Pharmaceutical composition for oral administration

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted